The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.
The arrival of gene therapy in the ‘90s brought hope for the treatment of genetic diseases. In recent years, new and emerging technologies have allowed us to overcome initial limitations, opening up the potential of tackling health conditions that were impossible to treat just a few years ago. Stargardt disease – a form of inherited blindness – is one such genetic condition, where researchers in the EU project StarT are working on novel gene therapy approaches to eventually help patients.
Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.
The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.
The arrival of gene therapy in the ‘90s brought hope for the treatment of genetic diseases. In recent years, new and emerging technologies have allowed us to overcome initial limitations, opening up the potential of tackling health conditions that were impossible to treat just a few years ago. Stargardt disease – a form of inherited blindness – is one such genetic condition, where researchers in the EU project StarT are working on novel gene therapy approaches to eventually help patients.
Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.